Malaysiakini
ENBM中文TA
Sign In
Subscribe
  • LifetimeACTIVEINACTIVEEXPIRED
  • Registered on:Renews on:
    ACTIVEINACTIVEEXPIRED
  • Subscribe
  • Renew
  • Extend Subscription
  • Settings
  • Contact Support
  • Sign Out
  • Latest
  • Videos
  • Opinions
  • Yoursay
  • Featured
  • Kini News Lab
  • KiniGuide
  • Sustainability
  • Events
  • Collab Content
  • TopTech
  • Our Team
  • Privacy Policy
  • Terms of Service
  • Advertise with us
  • Careers
  • Email
  • WhatsApp
  • File a complaint
  • Address
Malaysiakini
Subscribe
  • Latest
  • Videos
  • Opinions
  • Yoursay
  • Featured
  • Kini News Lab
  • KiniGuide
  • Sustainability
  • Events
  • Collab Content
  • TopTech
  • Our Team
  • Privacy Policy
  • Terms of Service
  • Advertise with us
  • Careers
  • Email
  • WhatsApp
  • File a complaint
  • Address
ENBM中文TA

      ANNOUNCEMENT

      He was the sole candidate proposed for the post during a state committee meeting.

      He was the sole candidate proposed for the post during a state committee meeting.

      Explainer: What we know about China-made vaccines
      Malaysiakini
      News
      Explainer: What we know about China-made vaccines

      Explainer: What we know about China-made vaccines

      ReutersPublished: Jan 1, 2021 8:58 AM | Updated: Jan 1, 2021 8:58 AM

      China was ahead in the global race to develop coronavirus vaccines with the most candidates in late stage of trials earlier this year. Its first approval of a homemade shot for the general public came on Thursday, yet with no detailed efficacy data.

      The following is what we know about China's vaccine development, efficacy data, and approval timeline.

      Which are the most advanced?

      Five vaccines from Sinovac Biotech, China National Pharmaceutical Group (Sinopharm), CanSinoBIO, and the Chinese Academy of Sciences are in late-stage clinical trials. None of them have released detailed efficacy data.

      Authorities approved a vaccine developed by...

      Five vaccines are in late-stage clinical trials. None have released detailed efficacy data.

      Deals for Covid-19 vaccines should be made openly, says Mahathir

      Deals for Covid-19 vaccines should be made openly, says Mahathir

      Explainer: How does AstraZeneca's vaccine compare with Pfizer-BioNTech?

      Explainer: How does AstraZeneca's vaccine compare with Pfizer-BioNTech?

      WHO marks year since Covid-19 began, urges fair vaccine distribution

      WHO marks year since Covid-19 began, urges fair vaccine distribution

      Sinopharm's Covid-19 vaccine 79pct effective, seeks approval in China

      Sinopharm's Covid-19 vaccine 79pct effective, seeks approval in China

      • comments0
      • facebook
      • whatsapp
      • x
      • comments0
      • facebook
      • whatsapp
      • x
      Related reports4

      Deals for Covid-19 vaccines should be made openly, says Mahathir

      31-12-2020

      Explainer: How does AstraZeneca's vaccine compare with Pfizer-BioNTech?

      31-12-2020

      WHO marks year since Covid-19 began, urges fair vaccine distribution

      30-12-2020

      Sinopharm's Covid-19 vaccine 79pct effective, seeks approval in China

      30-12-2020
      View Comments0

      Comment0

      By posting a comment, you agree to our Commenting Terms and Conditions as stipulated in full here.

      Do's and don'ts when posting comments in Malaysiakini

      TERMS & CONDITIONS

      Foul language, profanity, vulgarity, slanderous, personal attack, threatening, sexually-orientated comments or the use of any method of communication that may violate any law or create needless unpleasantness will not be tolerated. Antisocial behaviour such as "spamming" and "trolling" will be suspended. Violators run the risk of also being blocked permanently.

      REPORT VIOLATORS

      Please use the report feature that is available below each comment to flag offending comments for our moderators to take action. Do not take matters in your own hands to avoid unpleasant and unnecessary exchanges that may result in your own suspension or ban.

      Subscriber-only space:

      Are you a subscriber?

      Sign In

      Not yet a subscriber?

      Subscribe

      600 characters remaining
      mk-logo
      • whatsapp
      • telegram
      • youtube
      • facebook
      • x
      • instagram
      • tiktok
      • linkedin
      • About Us
      • Our Team
      • Privacy Policy
      • Terms of Service
      • Advertise with Us
      • Careers
      • Archive
      • Digital Network
      • KiniTV
      • FG Media
      • RSS Feeds
      • News
      • Opinion
      • Letters
      Contact Editorial
      envelopeeditor@malaysiakini.com
      Contact Subscription/Tech Support
      telephone+6017-323 0707
      envelopesubscribe@malaysiakini.com
      • Advertising
      • advertise@malaysiakini.com
      • advertise@fgmedia.my
      Mkini Dotcom Sdn Bhd
      (199901014818 / 489718-U)No. 9, Jalan 51/205A, Off Jalan Tandang, 46050 Petaling Jaya, Selangor
      Contact Editorial
      envelopeeditor@malaysiakini.com
      Contact Subscription/Tech Support
      telephone+603-7770 0017
      envelopesubscribe@malaysiakini.com
      @Kini
      No. 9, Jalan 51/205A, Off Jalan Tandang, 46050 Petaling Jaya, Selangor